Aberdeen Group plc Reduces Holdings in IDEXX Laboratories, Inc. $IDXX

Aberdeen Group plc lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 91,263 shares of the company’s stock after selling 1,374 shares during the quarter. Aberdeen Group plc owned 0.11% of IDEXX Laboratories worth $58,307,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. STF Management LP grew its position in IDEXX Laboratories by 1.3% in the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock valued at $665,000 after acquiring an additional 16 shares during the last quarter. Clearstead Trust LLC boosted its stake in shares of IDEXX Laboratories by 1.1% during the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock valued at $813,000 after purchasing an additional 16 shares during the period. MassMutual Private Wealth & Trust FSB grew its holdings in shares of IDEXX Laboratories by 4.4% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock worth $243,000 after purchasing an additional 16 shares during the last quarter. Moss Adams Wealth Advisors LLC grew its holdings in shares of IDEXX Laboratories by 3.3% in the third quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock worth $337,000 after purchasing an additional 17 shares during the last quarter. Finally, Stratos Wealth Partners LTD. increased its stake in IDEXX Laboratories by 1.7% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock worth $564,000 after buying an additional 18 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on IDXX. Wall Street Zen upgraded shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 7th. Piper Sandler lowered their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Morgan Stanley increased their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Leerink Partners set a $785.00 target price on IDEXX Laboratories in a research report on Monday, November 3rd. Finally, Barclays lowered their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Trading Up 2.0%

Shares of NASDAQ:IDXX opened at $629.35 on Monday. The company has a market capitalization of $50.25 billion, a PE ratio of 48.15, a P/E/G ratio of 3.83 and a beta of 1.67. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The business’s fifty day simple moving average is $684.99 and its 200-day simple moving average is $668.35.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the transaction, the executive vice president owned 9,823 shares in the company, valued at $6,352,730.56. The trade was a 53.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.